14/10/2022
Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs? For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...
14/10/2022
Why do VC’s not cut losses in time? A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....
29/09/2022
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic...
27/09/2022
MinervaX announces that EMA has awarded PRIME Status for its Group B Streptococcal vaccine MinervaX, a privately held Danish biotechnology company,today announces that EMA has awarded PRIME status for its vaccine against Group B Streptococcus (GBS).PRIME is aimed at...
26/09/2022
Are some diseases associated with a higher risk of venture capital losses? Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...
Side 1 af 1412345...10...»Sidste »
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments